

Review

# Repurposing metabolic drugs as anti-inflammatory agents

Andrew E. Hogan<sup>1,4,\*</sup>, Cian Davis<sup>2,4</sup>, Benjamin J. Jenkins<sup>3,4</sup>, Nicholas Jones<sup>3,4</sup>, and Donal O'Shea<sup>2,4,\*</sup>

**Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-like peptide-1 (GLP-1)-based therapies and sodium glucose co-transporter 2 (SGLT2) inhibitors, have entered the clinical management of bodyweight and metabolic disease with great success. With their expanded use, it is emerging that the benefits of these drugs extend beyond metabolic improvements into changes in chronic inflammation, potentially independent of those in metabolism. In this review, we discuss the impact of metabolic drugs on inflammatory comorbidities of metabolic disorders and beyond. We highlight the molecular mechanisms via which these drugs exert their anti-inflammatory actions and discuss their potential repurposing as direct anti-inflammatory agents.**

## Metabolic disorders and inflammation

Obesity is a complex chronic and progressive disease [1], which impacts over a billion individuals worldwide, a number that is rapidly increasing, with a prediction that over 50% of the world's population will be living with overweight or obesity by 2035 [2]. The economic cost to global health systems worldwide is estimated to be US\$4.32 trillion per annum [3]. The primary driver of this cost is embedded in the fact that obesity is strongly associated with numerous comorbidities, ranging from metabolic conditions, such as cardiovascular disease (CVD) and **type 2 diabetes mellitus (T2DM)** (see [Glossary](#)), to 13 different malignancies [4]. As a result, obesity can decrease the number of healthy-life years, and can reduce life expectancy by up to 14 years [5]. In 2019, higher than optimal bodyweight was linked to an estimated 5 million deaths from non-communicable obesity-related diseases, such as CVD, diabetes, and cancer [6]. The increases in morbidities and mortality are multifaceted [7] and, for many, include a genetic component, and environmental drivers.

However, one of the primary mechanisms underpinning obesity-related comorbidities is the presence of **chronic inflammation**, not only within dysfunctional adipose tissue depots, but also systemically, across the life-course. Over three decades ago, the first evidence emerged linking obesity, inflammation, and metabolic, with the observation that tumour necrosis factor (TNF) was elevated in obese adipose tissue and could directly drive insulin resistance [8]. Since then, numerous studies have linked obesity to elevated levels of many inflammatory cytokines, including TNF, interleukin (IL)-6, and IL-17 [9–13]. Similarly, research has linked obesity-related inflammation to the development of comorbidities [14] ([Figure 1](#)).

The clinical management of obesity has focussed on trying to reduce weight using lifestyle modification, pharmacotherapy, and surgical interventions [15–17]. With the continued use of these approaches, there is burgeoning evidence that their benefits extend far beyond improvements

## Highlights

Recent evidence from clinical use is highlighting the anti-inflammatory properties of two classes of metabolic drugs, glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter 2 (SGLT2) inhibitors.

The molecular underpinnings of the anti-inflammatory actions of these medications are emerging and suggest improvements in systemic metabolism paired with direct anti-inflammatory mechanisms, but large gaps in our understanding remain.

Understanding the mechanisms underlying the anti-inflammatory effects may reveal potential therapeutic opportunities outside of metabolic diseases.

<sup>1</sup>Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland


<sup>2</sup>St Vincent's University Hospital & University College Dublin, Dublin 4, Ireland

<sup>3</sup>Institute of Life Science, Swansea University Medical School, Swansea, UK

<sup>4</sup>These authors contributed equally to this work.

\*Correspondence:  
[Andrew.E.Hogan@mu.ie](mailto:Andrew.E.Hogan@mu.ie) (A.E. Hogan)  
and [info@dosheaendo.ie](mailto:info@dosheaendo.ie) (D. O'Shea).





**Figure 1.** Bi-directional interplay between obesity, inflammation, and comorbid diseases, such as type 2 diabetes mellitus, cardiovascular disease, metabolic liver disease, and dementia. Established drivers/contributors of obesity include genetics, poor food environment, reduced physical activity, reduced sleep hygiene and elevated stress. Low-grade chronic inflammatory mediators include interleukin (IL)-1, IL-6, IL-17, and tumour necrosis factor (TNF). Abbreviations: CRP, C-reactive protein; MASLD, metabolic dysfunction-associated steatotic liver disease. Figure created with BioRender.

in bodyweight and metabolic profiles, including improvements in cardiovascular, hepatic, and renal health, with reduced dementia and cancer risk. In parallel, a significant body of evidence is emerging detailing that the protective mechanisms of these obesity-focussed interventions extend beyond weight loss and improvements in metabolic profiles, with reduced inflammation a major component. Given this growing evidence and the evolving therapeutic landscape of anti-obesity medications, we focus here on two pharmacotherapies widely used in the setting of obesity and metabolic disease; GLP1-based therapies and SGLT2 inhibitors. We discuss their current clinical use, modes of action, and focus on the emerging benefits, and their direct anti-inflammatory effects.

### GLP-1-based medications

GLP-1 is a gut-derived multifaceted incretin peptide hormone first discovered in 1987 [18], which has a broad role in systemic metabolism, from controlling glucose metabolism through regulation of insulin secretion, gastrointestinal motility, food intake, and energy expenditure [19–21]. The classical actions (regulation of glucose homeostasis and food intake) of GLP-1 are mediated via the canonical GLP-1 receptor (GLP-1R), which is widely expressed across multiple sites, including the islet  $\beta$  cells and CNS [22]. In glucose metabolism, GLP-1 signalling can promote insulin secretion while inhibiting glucagon secretion, and loss of GLP-1R signalling increases glycaemic excursion after oral glucose challenge [23]. This effect is mediated locally in  $\beta$  cells, given that loss of CNS GLP-1R signalling only transiently impairs glucose homeostasis [24,25]. Mechanistically, GLP-1R signalling drives a cAMP-dependant crosstalk with membrane ion channels to support intracellular glucose metabolism [22]. Conversely, GLP-1R regulation of food intake is mediated centrally, as first reported in 1996 [20], and knockdown of GLP-1 CNS attenuates the impact of GLP-1R **agonist** (GLP-1RA) treatment on food intake and bodyweight [25]. The actions of GLP-1 in the CNS are complex, with widespread distribution of GLP-1R across the CNS, especially the hypothalamus [22]. One study, which genetically knocked out GLP-1R on specific hypothalamic feeding cells, concluded that classic homeostatic control regions of food intake are sufficient, but not individually necessary, for the effects of GLP-1RA [26]. In its native form, GLP-1 is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) [27]. Glucose metabolism improved in mice lacking DPP-4, or treated with DPP-4 inhibitors, highlighting the

### Glossary

**Agonist:** compound that activates a receptor, mimicking a biological molecule.

**Cardiovascular events:** incident that damages the heart or blood vessels.

**Chronic inflammation:** non-resolving condition underpinned by excessive inflammation, which damages tissues, organs, and/or systems.

**First-line drug:** first/preferred treatment for a disease, usually effective at controlling the condition.

**Glycaemic control:** maintenance of blood glucose levels within a desirable range to prevent both hypoglycaemia and hyperglycaemia.

**Glycosuria:** abnormal excretion/presence of glucose in the urine.

**Mitochondrial output:** production of energy in the form of ATP via cellular respiration.

**Type 2 diabetes mellitus (T2DM):** condition in which blood glucose levels are higher than normal because the body cannot use insulin effectively or cannot produce it enough.

therapeutic potential of targeting GLP-1 activity [28]. The first generation of GLP-1-targeted medications focussed on GLP-1RAs such as Exendin-4, a peptide isolated from Gila monster venom, and their beneficial impact on glucose metabolism [29]. Subsequent efforts focussed on the development of long-acting GLP-1RAs, which are resistant to DPP-4 enzymatic activity, such as liraglutide [30,31].

Over the past decade, we have observed the rapid expansion of GLP-1 therapies, with current generations including semaglutide and tirzepatide. As patient exposure to these medications increases, their benefits have extended beyond **glycaemic control** and weight regulation. For example, their impressive cardio and hepatic protective properties have resulted in numerous investigations assessing their independent benefits in the management of CVD and metabolic-associated liver disease. In parallel with the large body of clinical evidence for extra-metabolic benefits is the burgeoning evidence for their anti-inflammatory effects.


#### GLP-1RAs and cardiovascular health

The cardioprotective effects of GLP-1RAs have been extensively studied in numerous clinical trials, including randomised studies. The international, multicentre trials LEADER, SUSTAIN-6, REWIND, and SUMMIT [32–35] demonstrated the superiority of liraglutide, semaglutide, dulaglutide, and tirzepatide, respectively over placebo in terms of prevention of major adverse cardiac events in individuals with T2DM with both high risk and prior history of CVD. Benefiting from large sample sizes of 3200–9000, these trials provided robust evidence of GLP-1RA efficacy in primary and secondary prevention of **cardiovascular events**, and led to the recommendation of GLP-1RAs as **first-line drugs** in T2DM for primary and secondary prevention of cardiac events in recent collaborative European guidelines published by the European Society of Cardiology and the European Association for the Study of Diabetes [36].

Numerous studies demonstrated evidence for alternative cardioprotective mechanisms of action (Figure 2), including impairing pathological activation of macrophages by exendin-4, with associated reduction in atherosclerotic plaque development [37]; the amelioration of baseline chronic inflammation by liraglutide in individuals with T2DM, reflected by decreased serum C-reactive protein (CRP) levels following initiation of therapy [38]; improvement of basal cardiometabolic risk factors by reducing body mass index when administered in conjunction with lifestyle interventions [39]; and attenuation of atherosclerotic plaque development through a reduction in lipid deposition, in circulating inflammatory cytokines and leukocyte recruitment [40]. The anti-inflammatory effects of GLP-1RA are further supported by evidence from murine models of obesity, where GLP-1RAs reduced adipose tissue macrophage populations, as well as the expression and production of IL-6, TNF, and monocyte chemoattractant protein-1 (MCP-1) [41]. Similarly, in individuals with T2DM, the inflammatory macrophage marker soluble CD163 and production of TNF and IL-1 were reduced after 3 months of GLP-1RA therapy [42]. Mechanistically, GLP-1 treatment induced STAT3 expression, resulting in increases in alternatively activated (M2-like) macrophage-related molecules, such as IL-10, CD163, and CD204 [43]. This was further supported in a murine model of atherosclerosis, where GLP-1Ras, via increased STAT3 expression, polarised macrophages to the M2-like phenotype, leading to a reduction in IL-6 levels and improvements in atherosclerotic plaques [44] (Figure 3).

#### GLP-1RAs and liver health

Another major comorbidity of obesity and metabolic dysfunction is now termed ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) [45]. In addition to metabolic dysfunction, such as insulin resistance and dyslipidaemia, inflammation has been strongly linked to both the development and progression of MASLD [46]. Overwhelming clinical evidence has




Trends in Endocrinology & Metabolism

**Figure 2.** Overview of glucagon-like peptide 1 receptor agonist (GLP-1RA)-related protection in cardiovascular, hepatic, and neurological health. GLP-1RA use is linked to reduced major adverse cardiovascular events (MACEs) and hepatic steatosis in the setting of obesity and metabolic disease, and improved cognitive function in neurodegenerative diseases. Mechanistically, improvements in tissue and systemic metabolism, paired with reduced inflammation and macrophage polarisations, are the major drivers of benefits associated with GLP-1RAs. Abbreviations: CRP, C-reactive protein; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; ROS, reactive oxygen species; TNF, tumour necrosis factor. Figure created with BioRender.

demonstrated the benefits of GLP-1RAs on liver steatosis [47–50]: in LEAN, a randomised double-blind study, 39% of individuals randomised to liraglutide had resolution of definite steatohepatitis [48]; similarly, a Phase 2 trial showed that semaglutide treatment resulted in a significantly higher percentage of patients with resolution of metabolic dysfunction-associated steatohepatitis (MASH) compared with placebo [50]. SURPASS-3 MRI, a multicentred trial investigating the effect of the tirzepatide on liver fat content, showed significant reduction in liver fat content in individuals with T2DM compared with insulin [51]. In a 2024 retrospective analysis, GLP-1RA usage was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and T2DM [52].

The underlying mechanisms are likely multifaceted (Figure 2), including improvements in systemic insulin resistance. It is also proposed that GLP-1 is likely affecting hepatocytes directly, given that GLP-1R activation on hepatocytes promotes the expression of genes associated with lipid oxidation [53]. In addition, inflammation is a major contributor to MASLD; therefore, GLP-1-mediated reduction in inflammation is another mechanism underpinning improvements. Retrospective analysis of individuals with obesity and T2DM showed that those treated with liraglutide had reduced levels of the liver-derived inflammatory marker CRP [54]. In murine models of lipid-driven hepatic dysfunction, treatment with exendin-4 revealed GLP-1R-dependent reductions in hepatic macrophage infiltration and inflammation [37]. In another murine study, liraglutide treatment improved hepatic inflammation in a methionine choline-deficient (MCD) dietary model of liver disease; specifically, the authors noted a reduction in signatures associated with hepatic inflammatory



**Figure 3. Impact of obesity on macrophage biology and the reported changes achieved with glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy.** Obesity is associated with an increased frequency of inflammatory macrophages (M1-like), which contribute to elevated levels of interleukin (IL)-1, IL-6, monocyte chemoattractant protein-1 (MCP-1), and tumour necrosis factor (TNF) via increased NF- $\kappa$ B and NLRP3 signalling, with a reduction in IL-10 production. Data show that GLP-1RA therapy increases M2-like macrophages, leading to reduced IL-1 and TNF, with an increase in IL-10 production mediated by reduced inflammatory (NF- $\kappa$ B and NLRP3) signalling and increased STAT3 signalling. Figure created with BioRender.

macrophages and TNF transcripts [55]. Conversely, an increase in M2-like hepatic macrophage polarisation was observed upon liraglutide treatment, whereby *in vitro* treatment of Kupffer cells with liraglutide polarised them toward an M2-like phenotype via a cAMP–STAT3 signalling cascade [56]. In a pilot study of individuals with T2DM and MASLD, liraglutide treatment resulted in decreased histological hepatic-inflammation in most patients [57].

### GLP-1RAs and neuroprotection

The presence of a central GLP-1 secretory system that may act independently of gastrointestinal production [58] has directed research toward the potential role of GLP-1RAs in the central and peripheral nervous systems. Evidence for central GLP-1 anti-inflammatory actions comes from the observation that GLP-1R activation reduced TNF production in a murine model of sepsis; mechanistically, this was not mediated by haematopoietic or endothelial GLP-1Rs, but required central neuronal GLP-1R signalling [59]. As a central player in the modulation of neuroinflammation, GLP-1 receptor activation was demonstrated to block the release of proinflammatory cytokines, such as TNF and IL-1 $\alpha$ , from neurotoxic phenotype A1 astrocytes [60], which have themselves been shown to be key drivers of conditions with neurodegenerative elements, such as Parkinson's (PD) and Alzheimer's diseases (AD), the risk of developing each of which is elevated in individuals with T2DM [61].

Clinical data supporting GLP-1RAs as a treatment for PD have been encouraging, with randomised placebo-controlled trials of weekly exenatide in patients with moderate PD and daily lixisenatide in patients with early PD improving motor and cognition clinical assessment scores and delaying loss of motor skills, respectively compared with placebo [62,63]. The fact that improvements persisted after a medication washout period raises interesting questions about the precise nature and duration of the mechanism of action of GLP-1RAs in PD. Murine models treated with GLP-1 drugs, such as liraglutide, in the setting of AD demonstrated both general anti-inflammatory capacity, in the diminishing of deleterious reactive oxygen species (ROS) via dampening of oxidative




phosphorylation with beneficial effects for astrocytes, and more disease-specific activity in their protection against amyloid plaque and neurofibrillary tangle formations that are pathognomonic of the disease [64,65]. However, small-scale studies in humans, underpowered to demonstrate potential impacts on neuropsychiatric symptom control, showed positive effects on pathogenic pathways, such as slowing the decline in cerebral glucose metabolism and enhancing glucose transfer across the blood–brain barrier [66,67]. The Phase 2b ELAD study reported improved clinical and cognitive scores in patients with AD treated with liraglutide as well as a protective effect on brain volume compared with placebo; a caveat exists in that these represented secondary outcomes as per the trial protocol and the results await final publication [68] (Figure 2).

#### GLP-1RAs and other inflammatory conditions

In addition to their beneficial effects in cardiovascular and metabolic liver diseases, GLP-1 drugs have been explored in a range of inflammatory conditions, including psoriasis, an inflammatory skin condition [69,70]. GLP-1-based therapy modulates invariant natural killer T (iNKT) cells infiltration into psoriatic plaques, paired with an increase in the circulation. *In vitro* studies demonstrated that GLP-1 (both native peptide and liraglutide) treatment could trigger cAMP responses and subsequently reduce iNKT cell production of cytokines. Subsequent studies of GLP-1 and psoriasis noted a significant reduction in dermal  $\gamma\delta$ T cell frequencies and levels of IL-17, IL-23, and TNF, three causative inflammatory cytokines in psoriasis [71,72]. iNKT cells are involved in the regulation of adipose tissue [73], and obesity exerts a deleterious impact on the frequencies (peripheral and adipose tissue) and functional responses (including regulation of bodyweight) of these cells across the lifespan [73]. In murine models of obesity and cohorts of people with obesity, GLP-1-based therapy reversed obesity-related defects in iNKT cell frequencies, and promoted IL-10 production by these cells, further supporting its anti-inflammatory actions [74].

Acute kidney disease (AKD) and chronic kidney disease (CKD) are rising in incidence globally, with T2DM identified as an independent risk factor for both [75]. In cohorts of individuals with kidney disease, GLP-1 drug usage was associated with reduced major adverse kidney disease, and CKD-related deaths [76]. Mechanistically, in addition to the direct effect of GLP-1 on the kidney [77], GLP-1 modulation of macrophage phenotype and function has been implicated in the protective effects of GLP-1 in CKD [78]. In murine models of kidney disease, GLP-1 treatment significantly improved renal outcomes by decreasing the renal infiltration and proliferation of T cells, which resulted in decreased macrophage infiltration. Furthermore, *in vitro*, T cells stimulated in the presence of liraglutide showed decreased proliferation of both T helper (Th)-1 and Th17 cells [79] (Figure 4).

Emerging evidence is highlighting the potential benefits of GLP-1 therapies in the setting of cancer. Given that obesity is among the most significant drivers of cancers [80], a class of drugs that improve obesity might be expected to improve cancer outcomes. In a large retrospective cohort study with a 15-year follow up, GLP-1 drug usage was associated with a significant risk reduction in ten of 13 obesity-associated cancers [81]. Mechanistically, the reduction in insulin resistance and inflammation is likely a primary driver of this reduced risk. In addition, GLP-1 therapy can significantly improve natural killer (NK) cell anticancer functions [82], a critical immune population that is strongly limited by obesity [83,84]. Conversely, a later study highlighted the potential inhibitory role of GLP-1 on T cells, postulating that it might act as a T cell-negative co-stimulatory molecule. Using murine models of colorectal cancer, the study demonstrated that antagonism of GLP-1R signalling triggered antitumour immunity [85]. Further detailed studies in humans are required to determine whether inhibiting GLP-1 signalling drives antitumour immunity. Another outstanding issue requiring clarity is the expression of the GLP-1 receptor on immune cells. Although robust expression of GLP-1R has been shown across multiple T cell populations [85], how GLP-1 exerts



**Figure 4. Glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) therapy modulates conventional and unconventional T cell responses.** Data show that GLP-1 therapy increases anti-inflammatory invariant natural killer T (iNKT) cells producing interleukin (IL)-10 in the setting of obesity. In addition, inflammatory iNKT and  $\gamma\delta$ T cells are reduced in the plaques of patients with psoriasis, leading to decreases in IL-17 and tumour necrosis factor (TNF). Similarly, data show that GLP-1 can reduce CD4+ T cell production of inflammatory mediators, including IL-17 and interferon (IFN)  $\gamma$ . Figure created with BioRender.

its anti-inflammatory actions is incompletely understood, given that most immune cells do not express the GLP-1R, and its expression is limited to intestinal intra-epithelial lymphocytes [86].


### Sodium glucose co-transporter 2 inhibitors

SGLT2 inhibitors are routinely used in the treatment of T2DM. SGLT2 is expressed within the renal proximal tubule and is responsible for the reabsorption of ~90% of filtered glucose [87]. Consequently, highly selective inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, have been developed to prevent renal glucose uptake through SGLT2 and promote **glycosuria** to, ultimately, improve glycaemic control [88]. However, inhibiting SGLT2 only blocks the reabsorption of 30–50% of filtered glucose within the kidney [89]. As such, SGLT2 inhibitors administered either as a monotherapy or in combination with other glucose-lowering agents can regulate blood glucose levels in patients with T2DM [90]. The reduced plasma glucose concentrations resulting from SGLT2 inhibition also provide further clinical benefit to patients with T2DM, whereby the loss of calories from glucose excretion can intrinsically reduce patient body weight [91–93].

SGLT2 inhibitors have now been revealed to have novel roles beyond glycaemic control. For example, their impressive cardioprotective and renoprotective properties have resulted in them becoming synonymous with the management of heart failure and CKD [94–96] (Figure 5). Chronic inflammation has a central role in the pathogenesis of T2DM [97], CVD [98], and CKD [99], thus suggesting the potential of SGLT2 inhibitors to resolve inflammatory disease. Moreover, other T2DM drugs have previously demonstrated anti-inflammatory functions, whereby metformin has shown promise in the treatment of autoimmune disease [100]. Consequently, research is beginning to reveal the immunomodulatory properties of SGLT2 inhibitors, detailing their impact on the immune response [101].

### SGLT2 medications and cardiovascular health

The cardioprotective effects of SGLT2 inhibitors is a class-wide attribute, whereby canagliflozin [102], dapagliflozin [103], and empagliflozin [104] have been shown to reduce the severity of cardiovascular comorbidities in patients with T2DM. These findings led to a clinical trial, which showed that SGLT2 inhibitors reduced the risk of adverse cardiovascular outcomes in patients with heart failure, regardless of their diabetes status [96,105,106]. As a result, SGLT2 inhibitors



Trends in Endocrinology & Metabolism

**Figure 5. Protective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors on obesity-related comorbid diseases.** SGLT2 inhibitor use is linked to reduced major adverse cardiovascular events (MACEs) and kidney disease in the setting of obesity and metabolic disease. Mechanistically, improvements in tissue and systemic metabolism, paired with reduced inflammation and macrophage polarisations, are the major drivers of benefits associated with SGLT2 inhibitors. Abbreviations: IL, interleukin; MCP-1, monocyte chemoattractant protein-1; mTOR, mammalian target of rapamycin; TNF, tumour necrosis factor. Figure created with BioRender.

are increasingly integrated into treatment strategies against chronic heart failure. However, the glucose-lowering function of SGLT2 inhibitors is unlikely to be the main driver of their cardioprotective function [102]. Instead, distinct anti-inflammatory processes, independent of glycaemic control, contribute to improved cardiovascular health.

Ectopic fat deposition within the heart and adjacent vasculature induces local tissue inflammation. Interestingly, dapagliflozin was reported to reduce epicardial adipose tissue (EAT) volume in patients with T2DM and obesity [107], which could contribute to risk reduction in cardiovascular events. Similar reductions in EAT volume have also been described in response to canagliflozin [108]. Other SGLT2 inhibitors, such as empagliflozin, have been shown to reduce adipose tissue inflammation by promoting fat utilisation and modulating resident macrophage function [109,110]. To this end, empagliflozin enhances energy expenditure within the adipose through activation of AMP-activated protein kinase (AMPK) and promotion of adipose tissue browning, consequently suppressing diet-induced weight gain [109,110]. In terms of altered macrophage function within adipose tissue, empagliflozin induces a switch toward an M2-like phenotype, with reduced levels of proinflammatory cytokines, such as TNF $\alpha$ , measured within local tissues [109,110]. In addition, increased adipokine signalling has also been implicated in the anti-inflammatory function of dapagliflozin and empagliflozin within adipose tissue, where they inhibit proinflammatory cytokine production [111] and NLRP3 inflammasome activation [112]. Interestingly, reduced NLRP3 inflammasome activation appears to have a metabolic underpinning, in that increased  $\beta$ -hydroxybutyrate levels following SGLT2 inhibition attenuate inflammasome activation in macrophages [113]. Together, these findings demonstrate how the versatile functions of SGLT2 inhibitors converge to ameliorate inflammation and manage obesity.



Other aspects of cardiovascular health are also impacted by SGLT2 inhibition. For example, dapagliflozin can restrain atherogenesis by inducing an anti-inflammatory microenvironment that minimises endothelial cell dysfunction [114]. Specifically, TNF $\alpha$ -mediated stimulation is attenuated by dapagliflozin, reversing diet-induced changes in endothelial cell function to restore normal levels of vasorelaxation and macrophage infiltration [114]. Similarly, canagliflozin limits signalling through the IL-1 $\beta$  pathway to regulate the production of IL-6 and MCP-1 by vascular endothelial cells [115], again linking vascular health and the immunoregulatory effect of SGLT2 inhibition. Moreover, empagliflozin has also been demonstrated to modulate macrophage function to mitigate adverse coronary events [116]. Following 6 months of treatment with empagliflozin, provascular progenitor cells and M2-like macrophages were more abundant in the circulation and were accompanied by a reduction in oxidative stress and inflammatory granulocyte function, together establishing a landscape permissive for vasculature regeneration [116]. There is evidence to suggest that proinflammatory cytokine production by endothelial cells and differentiated macrophages is inhibited by dapagliflozin through its repression of the NF- $\kappa$ B pathway [117]. These studies highlight the multifaceted approach through which SGLT2 inhibitors realise their cardioprotective function.

Interestingly, nutrient sensing is engaged in several of these immunomodulatory processes. One example is AMPK, which responds to nutrient deprivation. In the context of cardioprotective function, the anti-inflammatory effect of canagliflozin on endothelial cell cytokine secretion is dependent on AMPK activation and downstream signalling through this pathway [115]. The influence of AMPK is not unique to canagliflozin, given that the cardioprotective function of empagliflozin has been related to AMPK-induced changes in autophagy [118]. There is evidence to suggest that this impact on metabolism extends further, wherein empagliflozin improves **mitochondrial output** to overcome the dysfunction characterised within this organelle upon cardiac arrest [119]. Mechanistically, changes in mitochondrial function upon empagliflozin treatment are attributed to repression of mitochondrial fission to re-establish larger mitochondria with greater respiratory capacities [120]. However, activation of AMPK upon SGLT2 inhibition does not follow a class-wide mechanism. To this end, canagliflozin significantly inhibits complex I of the electron transport chain, leading to breakdown of mitochondrial respiration and subsequent AMPK activation [121,122]. By comparison, both dapagliflozin and empagliflozin have been shown to either have a lesser effect, or even no effect, on complex I activity versus canagliflozin [121,123]. In addition, canagliflozin has off-target effects on mitochondrial glutamate dehydrogenase, compounding the inhibition of mitochondrial metabolism and, thus, altering the balance of ATP levels to those favourable for AMPK activation [123]. Consequently, these studies highlight the importance of appraising the specific anti-inflammatory and antimetabolic properties of individual members within this drug class.

#### SGLT2 inhibitors and kidney health

Several clinical trials, including those exploring the cardioprotective effect of SGLT2 inhibition, have also revealed that canagliflozin [102], dapagliflozin [103], and empagliflozin [124] reduce the risk and severity of adverse renal outcome in patients with T2DM. Again, the renoprotective properties of SGLT2 inhibitors improve patient outcomes in CKD [125], resulting in new guidance recommending their use for the treatment of CKD and other renal disorders. Similar to the cardioprotective effects of SGLT2 inhibition, the renoprotective properties of these antidiabetic drugs are founded upon several anti-inflammatory mechanisms.

There are several common mechanisms that underpin the renoprotective and cardioprotective effects of SGLT2 inhibitors. For instance, empagliflozin has been shown to inhibit NF- $\kappa$ B activation, reduce proinflammatory cytokine production, and alleviate renal inflammation [126].

Macrophages treated with empagliflozin also display attenuated NF- $\kappa$ B signalling, which again inhibits the secretion of a range of proinflammatory cytokines [127]. Changes in mitochondrial metabolism also have a central role in mediating the renoprotection offered by SGLT2 inhibitors. Specifically, a marked reduction in the urinary levels of mitochondrial DNA and IL-1 $\beta$  following empagliflozin treatment suggests reduced mitochondrial damage and a concomitant amelioration of inflammation [128]. This is likely attributable to the mitochondrial biogenesis that empagliflozin promotes by preventing mitochondrial fragmentation within renal proximal tubular cells [129]. These changes in mitochondrial dynamics are coupled to AMPK activation [129,130], whereas dapagliflozin has been demonstrated to attenuate renal fibrosis in CKD by reversing MAPK-mediated alterations in mitochondrial function [131], again highlighting the importance of manipulating cellular metabolism to alleviate inflammation.


Research exploring changes in mitochondrial function SGLT2 inhibition also hint that mTOR activation is suppressed under these conditions [129]. Following dapagliflozin treatment, renal proximal tubular cells exhibit reduced mTOR activity, rewiring mitochondrial metabolism to drive itaconate synthesis, which then inhibits the activation of the NLRP3 inflammasome [132]. Moreover, dapagliflozin-mediated changes in the mTOR/AMPK signalling axis are central to its initiation of renal autophagy and subsequent anti-inflammatory function within the kidney [133]. Furthermore, canagliflozin and empagliflozin are also able to suppress mTOR in a range of human kidney cell types [134], indicating that there is a class-wide effect on mTOR activity. Collectively, there is a wealth of evidence describing the anti-inflammatory effects of SGLT2 inhibitors that contribute to both their renoprotective and cardioprotective function.

#### SGLT2 inhibitors and other inflammatory conditions

Given the burgeoning success of repositioning SGLT2 inhibitors into the treatment frameworks of CVD and CKD, exciting new studies have explored the use of canagliflozin, dapagliflozin, and empagliflozin in other inflammatory diseases. For instance, since autoimmunity is characterised by chronic inflammation arising from T cell hyperactivation, and canagliflozin has been shown to modulate human T cell function via metabolic reprogramming, the anti-inflammatory effects of SGLT2 inhibitors have been considered in this context [101]. Notably, early T cell receptor signalling events are impaired by canagliflozin, which impacts downstream signalling through the ERK/mTOR/MYC axis, preventing the metabolic rewiring required following T cell receptor-mediated activation [101]. Thereafter, T cell effector function, such as cytokine production, is heavily constrained by canagliflozin, which also retains this immunosuppressive function on autoimmune patient-derived T cells [101]. In the setting of immune thrombocytopenia (ITP), an autoimmune condition defined by autoreactive platelet destruction, empagliflozin has demonstrated immunomodulatory properties by skewing human T cell differentiation toward a regulatory phenotype [135]. Again, there was a metabolic foundation to these changes, whereby mTOR activity was impaired by empagliflozin, thus inhibiting the upregulation of glycolysis and shifting instead toward oxidative respiration [135]. Importantly, empagliflozin maintained these immunomodulatory functions in patient-derived T cells [135], further supporting the repurposing of SGLT2 inhibitors for the treatment of autoimmune disease. These findings are strengthened by emerging murine analyses, whereby canagliflozin alleviated an imiquimod-induced model of psoriasis by reducing cutaneous concentrations of inflammatory cytokines [136]. Excitingly, recent analyses in patients with T2DM and comorbid inflammatory skin conditions revealed that those receiving SGLT2 inhibitor treatment were at significantly less risk of developing new-onset alopecia areata, vitiligo, seborrheic dermatitis, and acne [137]. However, the risk of new-onset psoriasis was slightly increased by SGLT2 inhibitors [137], which perhaps advocates for further analyses of the efficacy of specific members within this class of drug in the treatment of autoimmunity, alongside research into individual autoimmune conditions on a case-by-case basis. Promisingly, similar research also

demonstrated that SGLT2 inhibitors have a protective effect against inflammatory skin conditions [138]. The marked reduction in the risk of developing vitiligo [138] is particularly interesting, given that T cell-mediated responses have a central role in the pathogenesis of this disease [139]. Outside of their influence on T cell function, SGLT2 inhibitors are also well tolerated in systemic lupus erythematosus [140], reducing the risk of nephritis and offering cardioprotective and renoprotective benefits in some patient cohorts [141]. Together, these findings provide a foundation for the clinical development of SGLT2 inhibitors as therapeutic agents in autoimmune conditions, particularly those burdened by heightened T cell function (Figure 6).

The use of SGLT2 inhibitors in other inflammatory conditions also warrants further investigation. Growing research is considering the use of SGLT2 inhibitors in conditions of hepatic inflammation, where they are well tolerated in patients with T2DM and concomitant liver cirrhosis [142], reducing the rate of mortality versus other antidiabetic drugs [143]. These findings are being expanded into conditions such as MASLD, in which SGLT2 inhibitors restrained steatosis and fibrosis in patients with T2DM and comorbid liver disease [144]. Once more, the therapeutic benefit of SGLT2 inhibition in conditions of hepatic inflammation has been linked to an immunomodulatory effect on T cell function. In this instance, empagliflozin was shown to alleviate MASH by inhibiting the activation of CD8+ T cells [145]. Interestingly, this immunosuppressive effect on pathogenic CD8+ T cell responses was again supported by metabolic reprogramming, whereby elevated rates of ketogenesis promoted the production of  $\beta$ -hydroxybutyric acid, in turn suppressing interferon regulatory factor 4 (IRF4), a key determinant of CD8+ T cell activation [145]. Other recent examples extend to the reduction in gout flare-ups in patients with T2DM receiving SGLT2 inhibitors [146], in addition to the alleviation of pathological aging through improved immune-mediated clearance of senescent cells following treatment with canagliflozin [147]. The potential mechanisms through which the already-described anti-inflammatory effects of SGLT2 inhibitors could benefit ‘inflamm-aging’ have also been extensively reviewed [148].



**Figure 6. Impact of sodium glucose co-transporter 2 (SGLT2) inhibitors on macrophage and T cell biology.** Data show that SGLT2 inhibitors increase anti-inflammatory M2-like macrophages producing interleukin (IL)-10, with notable reductions in IL-1, IL-6, monocyte chemoattractant protein-1 (MCP-1), and tumour necrosis factor (TNF) via reduced NF- $\kappa$ B and NLRP3 signalling. In addition, SGLT2 inhibitors can reduce CD4+ T cell production of inflammatory mediators, including IL-17 and interferon (IFN)  $\gamma$ , via reduced T cell receptor (TCR) signalling and metabolism. Abbreviation: mTOR, mammalian target of rapamycin. Figure created with BioRender.

Overall, these findings underline the ever-expanding uses of SGLT2 inhibitors in the treatment of inflammatory disease.

### Concluding remarks and future perspectives

The emergence over the past 25 years of GLP-1RAs and SGLT2 inhibitors to manage T2DM has revolutionised treatment goals for patients living with the disease. Studies investigating these drugs are leading to a richer understanding of not only how obesity drives inflammation, but also how alterations in specific intracellular pathways are common to obesity, T2DM, and other inflammatory conditions.

The additional recognition of direct anti-inflammatory actions of both classes of drug has been followed by a series of investigations to understand the mechanisms that underpin these actions, opening new indications for the use of their outside of T2DM and obesity, as outlined in this review. There is extensive evidence to support the repurposing of GLP-1RAs and SGLT2 inhibitors in a range of obesity-related comorbidities, which are often driven by chronic inflammation. Given the ever-growing burden of obesity [2] and the economic appeal (both financially and temporally) of drug repurposing [149], investigating the protective properties of GLP-1RA and SGLT2 inhibitors in other inflammatory settings, such as cardio-, renal-, neuro-, hepatic-inflammatory conditions and ‘inflamm-aging’, has become a burgeoning area of research. Understanding the molecular mechanisms that drive the immunomodulatory properties of GLP-1RA and SGLT2 inhibition is critical to harness their potential for repurposing, especially beyond obesity. With the rapidly increasing portfolio of GLP-1RAs and their expanding use in the management of obesity, their anti-inflammatory properties are clearer than ever; however, we lack a full understanding of the major molecular pathways mediating these effects. Similarly, although ongoing research continues to uncover the mechanisms underpinning the cardio- and renoprotective effects of SGLT2 inhibition, the dominant mechanisms through which highly selective inhibitors mediate their effect remain unknown.

Furthering our understanding of the predominant molecular mechanisms governing these immunomodulatory effects, particularly resolving class-wide versus drug-specific effects, would allow more targeted use in obesity-related inflammatory disease. The major unknown that the community needs to address is whether the anti-inflammatory effects of these drugs extend beyond weight loss and improved glycaemic control. In addition, several other important questions remain (see [Outstanding questions](#)). Growing *in vitro* and animal model data support a direct immunomodulatory effect, and clinical trials in patients without obesity will be required, but there is a strong potential for the repurposing of these drugs for a range of inflammatory conditions.

### Acknowledgements

A.E.H. and D.O.S. are supported by a Health Research Board Grant (ILP-POR-2024-019). N.J. is supported by an MRC New Investigator Research Grant (MR/X000095/1).

### Declarations of interest

The authors declare no conflicts of interest.

### References

1. Bray, G.A. *et al.* (2017) Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes. Rev.* 18, 715–723
2. NCD Risk Factor Collaboration (NCD-RisC) (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. *Lancet* 403, 1027–1050
3. Mahase, E. (2023) Global cost of overweight and obesity will hit \$4.32tn a year by 2035, report warns. *BMJ* 380, 523
4. Kivimäki, M. *et al.* (2022) Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. *Lancet Diabetes Endocrinol.* 10, 253–263
5. Nyberg, S.T. *et al.* (2018) Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. *Lancet Public Health* 3, e490–e497

### Outstanding questions

Can we separate the anti-inflammatory effects of GLP-1RAs and SGLT2 inhibitors from improvements in systemic metabolism?

Do the direct effects of GLP-1RAs and SGLT2 inhibitors on immune cells extend beyond macrophages and T cells?

What are the molecular underpinnings of the immune effects? Are they signalling mediated, cellular metabolism mediated, or both?

Are the anti-inflammatory responses tissue specific?

At the doses used therapeutically, will the tissue concentrations of SGLT2 inhibitors be sufficient to elicit anti-inflammatory responses?

Are the immune cell effects, especially with GLP-1 therapies, receptor mediated?

6. GBD 2019 Risk Factors Collaborators (2020) Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396, 1223–1249
7. Gonzalez-Muniesa, P. *et al.* (2017) Obesity. *Nat. Rev. Dis. Primers* 3, 17034
8. Hotamisligil, G.S. *et al.* (1993) Adipose expression of tumor necrosis factor- $\alpha$ : direct role in obesity-linked insulin resistance. *Science* 259, 87–91
9. Popko, K. *et al.* (2010) Proinflammatory cytokines IL-6 and TNF- $\alpha$  and the development of inflammation in obese subjects. *Eur. J. Med. Res.* 15, 120–122
10. Alzamil, H. (2020) Elevated serum TNF- $\alpha$  is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. *J. Obes.* 2020, 5076858
11. Roytblat, L. *et al.* (2000) Raised interleukin-6 levels in obese patients. *Obes. Res.* 8, 673–675
12. Winer, S. *et al.* (2009) Obesity predisposes to Th17 bias. *Eur. J. Immunol.* 39, 2629–2635
13. Bergin, R. *et al.* (2022) Mucosal-associated invariant T cells are associated with insulin resistance in childhood obesity, and disrupt insulin signalling via IL-17. *Diabetologia* 65, 1012–1017
14. Rohm, T.V. *et al.* (2022) Inflammation in obesity, diabetes, and related disorders. *Immunity* 55, 31–55
15. Bouzalmate Hajjaj, A. *et al.* (2022) A systematic review and meta-analysis of weight loss in control group participants of lifestyle randomized trials. *Sci. Rep.* 12, 12252
16. Yao, H. *et al.* (2024) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. *BMJ* 384, e076410
17. Salte, O.B.K. *et al.* (2024) Ten-year outcomes following Roux-en-Y gastric bypass vs duodenal switch for high body mass index: a randomized clinical trial. *JAMA Netw. Open* 7, e2414340
18. Mojsov, S. *et al.* (1987) Insulinotropin: glucagon-like peptide I (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. *J. Clin. Invest.* 79, 616–619
19. Tang-Christensen, M. *et al.* (1996) Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. *Am. J. Phys.* 271, R848–R856
20. Turton, M.D. *et al.* (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* 379, 69–72
21. O'Donnell, C. *et al.* (2024) GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. *Obesity* 32, 2077–2081
22. Drucker, D.J. (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metab.* 27, 740–756
23. Edwards, C.M. *et al.* (1999) Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39. *Diabetes* 48, 86–93
24. Lamont, B.J. *et al.* (2012) Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. *J. Clin. Invest.* 122, 388–402
25. Sisley, S. *et al.* (2014) Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. *J. Clin. Invest.* 124, 2456–2463
26. Burneister, M.A. *et al.* (2017) The hypothalamic glucagon-like peptide 1 receptor is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice. *Diabetes* 66, 372–384
27. Kieffer, T.J. *et al.* (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. *Endocrinology* 136, 3585–3596
28. Marguet, D. *et al.* (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. *Proc. Natl. Acad. Sci. U. S. A.* 97, 6874–6879
29. Kolterman, O.G. *et al.* (2003) Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. *J. Clin. Endocrinol. Metab.* 88, 3082–3089
30. Knudsen, L.B. *et al.* (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. *J. Med. Chem.* 43, 1664–1669
31. Buse, J.B. *et al.* (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet* 374, 39–47
32. Gerstein, H.C. *et al.* (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet* 394, 121–130
33. Marso, S.P. *et al.* (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* 375, 311–322
34. Marso, S.P. *et al.* (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* 375, 1834–1844
35. Chuang, M.H. *et al.* (2024) Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. *JAMA Netw. Open* 7, e2427258
36. Cosentino, F. *et al.* (2019) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). *Eur. Heart J.* 41, 255–323
37. Wang, Y. *et al.* (2014) Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. *Br. J. Pharmacol.* 171, 723–734
38. Mozaffari, N. *et al.* (2024) Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: a GRADE-assessed systematic review and dose-response meta-analysis of controlled trials. *PharmaNutrition* 30, 100409
39. Wilding, J.P.H. *et al.* (2021) Once-weekly semaglutide in adults with overweight or obesity. *N. Engl. J. Med.* 384, 989–1002
40. Rakipovski, G. *et al.* (2018) The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-/-) and LDLr(-/-) mice by a mechanism that includes inflammatory pathways. *JACC Basic Transl. Sci.* 3, 844–857
41. Lee, Y.S. *et al.* (2012) Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. *Diabetologia* 55, 2456–2468
42. Hogan, A.E. *et al.* (2014) Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. *Diabetologia* 57, 781–784
43. Shiraishi, D. *et al.* (2012) Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. *Biochem. Biophys. Res. Commun.* 425, 304–308
44. Vinue, A. *et al.* (2017) The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. *Diabetologia* 60, 1801–1812
45. Rinella, M.E. *et al.* (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology* 78, 1966–1986
46. Lim, S. *et al.* (2021) Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. *Trends Endocrinol. Metab.* 32, 500–514
47. Vanderheiden, A. *et al.* (2016) Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin. *J. Clin. Endocrinol. Metab.* 101, 1798–1806
48. Armstrong, M.J. *et al.* (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 387, 679–690
49. Bouchi, R. *et al.* (2017) Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. *Endocr. J.* 64, 269–281
50. Newsome, P.N. *et al.* (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N. Engl. J. Med.* 384, 1113–1124
51. Gastaldello, A. *et al.* (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. *Lancet Diabetes Endocrinol.* 10, 393–406
52. Kanwal, F. *et al.* (2024) GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. *JAMA Intern. Med.* 184, 1314–1323



53. Svegliati-Baroni, G. *et al.* (2011) Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. *Liver Int.* 31, 1285–1297
54. Varanasi, A. *et al.* (2012) Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. *Endocr. Pract.* 18, 140–145
55. Somm, E. *et al.* (2021) The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. *Transl. Res.* 227, 75–88
56. Li, Z. *et al.* (2019) Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway. *Biochem. Biophys. Res. Commun.* 510, 20–26
57. Eguchi, Y. *et al.* (2015) Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). *Hepatol. Res.* 45, 269–278
58. Brierley, D.I. *et al.* (2021) Central and peripheral GLP-1 systems independently suppress eating. *Nat. Metab.* 3, 258–273
59. Wong, C.K. *et al.* (2024) Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. *Cell Metab.* 36, 130–143
60. Cui, Q.N. *et al.* (2022) The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. *Br. J. Pharmacol.* 179, 715–726
61. Liang, P. *et al.* (2023) Neurotoxic A1 astrocytes promote neuronal ferroptosis via CXCL10/CXCR3 axis in epilepsy. *Free Radic. Biol. Med.* 195, 329–342
62. Athauda, D. *et al.* (2017) Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *Lancet* 390, 1664–1675
63. Meissner, W.G. *et al.* (2024) Trial of lisenatide in early Parkinson's disease. *N. Engl. J. Med.* 390, 1176–1185
64. Zheng, J. *et al.* (2021) GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease. *Mol. Metab.* 47, 101180
65. Paladugu, L. *et al.* (2021) Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer's disease. *Int. J. Mol. Sci.* 22, 860
66. Gejl, M. *et al.* (2017) Blood-brain glucose transfer in Alzheimer's disease: effect of GLP-1 analog treatment. *Sci. Rep.* 7, 17490
67. Gejl, M. *et al.* (2016) In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. *Front. Aging Neurosci.* 8, 108
68. Femminella, G.D. *et al.* (2019) Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). *Trials* 20, 191
69. Hogan, A.E. *et al.* (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. *Diabetologia* 54, 2745–2754
70. Ahern, T. *et al.* (2012) Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. *J. Eur. Acad. Dermatol. Venereol.* 27, 1440–1443
71. Buysschaert, M. *et al.* (2014) Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal gamma delta T-cell number: a prospective case-series study. *Br. J. Dermatol.* 171, 155–161
72. Lin, L. *et al.* (2022) Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. *J. Dermatolog. Treat.* 33, 1428–1434
73. Lynch, L. *et al.* (2012) Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. *Immunity* 37, 574–587
74. Lynch, L. *et al.* (2016) iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. *Cell Metab.* 24, 510–519
75. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 105, S117–S314
76. Perkovic, V. *et al.* (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N. Engl. J. Med.* 391, 109–121
77. Muskiet, M.H.A. *et al.* (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. *Nat. Rev. Nephrol.* 13, 605–628
78. Sourris, K.C. *et al.* (2024) Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. *Kidney Int.* 105, 132–149
79. Moschovaki Filippidou, F. *et al.* (2020) Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation. *Am. J. Pathol.* 190, 400–411
80. Calle, E.E. *et al.* (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N. Engl. J. Med.* 348, 1625–1638
81. Wang, L. *et al.* (2024) Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. *JAMA Netw. Open* 7, e2421305
82. De Barra, C. *et al.* (2023) Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function. *Obesity* 31, 1787–1797
83. De Barra, C. *et al.* (2023) NK cells vs. obesity: a tale of dysfunction & redemption. *Clin. Immunol.* 255, 109744
84. Michelet, X. *et al.* (2018) Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. *Nat. Immunol.* 19, 1330–1340
85. Ben Nasr, M. *et al.* (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. *Cell Metab.* 36, 1302–1319
86. Wong, C.K. *et al.* (2022) Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation. *Cell Metab.* 34, 1514–1531
87. Vallon, V. *et al.* (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. *J. Am. Soc. Nephrol.* 22, 104–112
88. Mosley, J.F., 2nd *et al.* (2015) Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. *P T* 40, 451–462
89. Liu, J.J. *et al.* (2012) Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? *Diabetes* 61, 2199–2204
90. Scheen, A.J. (2015) Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. *Drugs* 75, 33–59
91. List, J.F. and Whaley, J.M. (2011) Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. *Kidney Int. Suppl.* 120, S20–S27
92. Bays, H.E. *et al.* (2014) Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. *Obesity* 22, 1042–1049
93. Bolinder, J. *et al.* (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. *J. Clin. Endocrinol. Metab.* 97, 1020–1031
94. Neal, B. *et al.* (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N. Engl. J. Med.* 377, 644–657
95. Petrie, M.C. *et al.* (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. *JAMA* 323, 1353–1368
96. Packer, M. *et al.* (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. *N. Engl. J. Med.* 383, 1413–1424
97. Tsalamandris, S. *et al.* (2019) The role of inflammation in diabetes: current concepts and future perspectives. *Eur. Cardiol.* 14, 50–59
98. Henein, M.Y. *et al.* (2022) The role of inflammation in cardiovascular disease. *Int. J. Mol. Sci.* 23, 12906
99. Mihai, S. *et al.* (2018) Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. *J. Immunol. Res.* 2018, 2180373
100. Sun, F.F. *et al.* (2020) Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials. *Lupus Sci. Med.* 7, e000429
101. Jenkins, B.J. *et al.* (2023) Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. *Cell Metab.* 35, 1132–1146
102. Perkovic, V. *et al.* (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N. Engl. J. Med.* 380, 2295–2306
103. Wiviott, S.D. *et al.* (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* 380, 347–357

104. Zinman, B. *et al.* (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N. Engl. J. Med.* 373, 2117–2128
105. Spertus, J.A. *et al.* (2022) The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. *Nat. Med.* 28, 809–813
106. Solomon, S.D. *et al.* (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N. Engl. J. Med.* 387, 1089–1098
107. Iacobellis, G. and Gra-Mendez, S. (2020) Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. *Obesity* 28, 1068–1074
108. Yagi, S. *et al.* (2017) Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. *Diabetol. Metab. Syndr.* 9, 78
109. Xu, L. *et al.* (2017) SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. *EBioMedicine* 20, 137–149
110. Xu, L. *et al.* (2019) Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. *BMJ Open Diabetes Res. Care* 7, e000783
111. Kabir, M. *et al.* (2023) Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model. *Obesity* 31, 1798–1811
112. Ye, T. *et al.* (2022) Empagliflozin attenuates obesity-related kidney dysfunction and NLRP3 inflammasome activity through the HO-1-adiponectin axis. *Front. Endocrinol.* 13, 907984
113. Kim, S.R. *et al.* (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. *Nat. Commun.* 11, 2127
114. Gaspari, T. *et al.* (2018) Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. *Diab. Vasc. Dis. Res.* 15, 64–73
115. Mancini, S.J. *et al.* (2018) Canagliflozin inhibits interleukin-1 $\beta$ -stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. *Sci. Rep.* 8, 5276
116. Hess, D.A. *et al.* (2019) SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. *Cell Metab.* 30, 609–613
117. Abdollahi, E. *et al.* (2022) Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF $\kappa$ B activation in human endothelial cells and differentiated macrophages. *Eur. J. Pharmacol.* 918, 174715
118. Ren, C. *et al.* (2021) Sodium-glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. *Front. Pharmacol.* 12, 664181
119. Tan, Y.K. *et al.* (2021) Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function after cardiac arrest in rats by enhancing mitochondrial energy metabolism. *Front. Pharmacol.* 12, 758080
120. Zou, R.J. *et al.* (2022) Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. *Cardiovasc. Diabetol.* 21, 106
121. Hawley, S.A. *et al.* (2016) The Na<sup>+</sup>/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. *Diabetes* 65, 2784–2794
122. Villani, L.A. *et al.* (2016) The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. *Mol. Metab.* 5, 1048–1056
123. Secker, P.F. *et al.* (2018) Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. *Cell Death Dis.* 9, 226
124. Wanner, C. *et al.* (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. *N. Engl. J. Med.* 375, 323–334
125. Herrington, W.G. *et al.* (2023) Empagliflozin in patients with chronic kidney disease. *N. Engl. J. Med.* 388, 117–127
126. Ashrafi Jigheh, Z. *et al.* (2019) Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. *Iran J. Basic Med. Sci.* 22, 384–390
127. Lee, N. *et al.* (2021) Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK/NF- $\kappa$ B, MKK7/JNK, and JAK2/STAT1 signalling pathways. *J. Immunol. Res.* 2021, 9944880
128. Lee, H. *et al.* (2022) Empagliflozin suppresses urinary mitochondrial DNA copy numbers and interleukin-1 $\beta$  in type 2 diabetes patients. *Sci. Rep.* 12, 19103
129. Lee, Y.H. *et al.* (2019) Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. *Am. J. Physiol. Renal Physiol.* 317, F767–F780
130. Liu, X. *et al.* (2020) Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. *Metabolism* 111, 154334
131. Zeng, J. *et al.* (2023) Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF- $\beta$ 1/MAPK mediated mitochondrial damage. *Front. Pharmacol.* 14, 1095487
132. Ke, Q. *et al.* (2022) SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney. *FASEB J.* 36, e22078
133. Jaikumkao, K. *et al.* (2021) Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats. *J. Cell. Physiol.* 236, 6424–6440
134. Schaub, J.A. *et al.* (2023) SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. *J. Clin. Invest.* 133, e164486
135. Qin, J. *et al.* (2022) Empagliflozin modulates CD4<sup>+</sup> T-cell differentiation via metabolic reprogramming in immune thrombocytopenia. *Br. J. Haematol.* 198, 765–775
136. Ridha-Salman, H. *et al.* (2024) The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. *Naunyn Schmiedeberg's Arch. Pharmacol.* 398, 2695–2715
137. Ma, K.S. *et al.* (2024) Effects of sodium-glucose cotransporter-2 inhibitors on inflammatory skin diseases in patients with type 2 diabetes. *J. Am. Acad. Dermatol.* 91, 934–936
138. Shen, C.H. *et al.* (2024) Sodium-glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseases. *Br. J. Dermatol.* 191, 467–468
139. Riding, R.L. and Harris, J.E. (2019) The role of memory CD8(+) T cells in vitiligo. *J. Immunol.* 203, 11–19
140. Wang, H. *et al.* (2022) Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. *RMD Open* 8, e002686
141. Yen, F.S. *et al.* (2024) Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. *JAMA Netw. Open* 7, e2416578
142. Saffo, S. *et al.* (2021) SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: a tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. *J. Diabetes* 13, 265–269
143. Saffo, S. *et al.* (2021) Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. *Diabetes Obes. Metab.* 23, 2402–2408
144. Wei, Q. *et al.* (2021) Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. *Front. Endocrinol.* 12, 635556
145. Liu, W. *et al.* (2024) SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) T cell activation. *Cell Metab.* 36, 2245–2261
146. Wei, J. *et al.* (2023) Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. *JAMA Netw. Open* 6, e2330885
147. Katsuomi, G. *et al.* (2024) SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. *Nat. Aging* 4, 926–938
148. Schönberger, E. *et al.* (2023) Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging. *Int. J. Environ. Res. Public Health* 20, 6671
149. Pushpakom, S. *et al.* (2019) Drug repurposing: progress, challenges and recommendations. *Nat. Rev. Drug Discov.* 18, 41–58